Aim: This study examined catechol-Omethyltransferase (COMT) DNA methylation in the peripheral blood of schizophrenia patients and also in healthy controls to investigate its potential use as a peripheral biomarker of schizophrenia and its relations with the clinical variables of schizophrenia patients.
Aim: This study examined catechol-Omethyltransferase (COMT) DNA methylation in the peripheral blood of schizophrenia patients and also in healthy controls to investigate its potential use as a peripheral biomarker of schizophrenia and its relations with the clinical variables of schizophrenia patients.
Methods:
We examined the DNA methylation levels of COMT using genomic DNA from the peripheral blood of schizophrenia patients (n = 138) and healthy control participants (n = 132); all were Malaysian Malays. The extracted DNA was bisulfite converted, and the percentage methylation ratio value was calculated based on the results following a MethyLight protocol analysis.
Results:
The percentage methylation ratio of COMT was lower in schizophrenia than it was in the healthy controls (P < 0.001) and was different between the body mass index (P = 0.003) and antipsychotic (P = 0.004) groups. The COMT DNA methylation rate was lower in patients receiving atypical antipsychotics (P = 0.004) and risperidone (P = 0.049) as compared to typical antipsychotics. The Excitement and Depressed subdomains of the Positive and Negative Syndrome Scale were inversely related (P < 0.001) and therefore predictors (Excitement: b = −11.396, t = −4.760, P < 0.001; Depressed: b = −7.789, t = −3.487, P = 0.001) of COMT DNA methylation.
Conclusion:
Our results suggested that the methylation level was affected by the severity of the clinical symptoms of schizophrenia and might also be influenced by pharmacological treatment. The epigenetic alteration of COMT in the peripheral blood could be a potential peripheral biomarker of schizophrenia.
Key words: COMT, DNA methylation, epigenetics, genetics in psychiatry, schizophrenia. M ULTIPLE THEORIES IN regards to the etiology of schizophrenia have been proposed; however, the neurodevelopment and neurodegenerative models have been put forth as the leading causes associated with the clinical symptoms in schizophrenia. 1 Catechol-O-methyltransferase (COMT) is an enzyme involved in the degradation of dopamine; based on the dopamine hypothesis, schizophrenia is associated with decreased dopamine activity in the prefrontal cortex. 2 Accumulating evidence has suggested the involvement of COMT genotypes in the pathophysiology of schizophrenia. 3 The most recent meta-analysis indicated that COMT was associated with psychological symptoms and cognitive characteristics as well as antipsychotic response in schizophrenia patients. 4 In addition, COMT has also been found to be associated with positive symptoms, 5, 6 negative symptoms, 7, 8 manic symptoms, 9 and cognitive deficits in schizophrenia. [10] [11] [12] In terms of epigenetic studies, investigations into the association between COMT DNA methylation and schizophrenia have focused on two isoforms: the soluble isoform (S-COMT) and the membranebound isoform (MB-COMT). 13 The MB-COMT enzyme is thought to be involved with dopamine and noradrenergic neurotransmission and therefore widely distributed in the peripheral blood and brain, while the S-COMT enzyme plays a role in the elimination of active or toxic biological products and acts as a barrier between the blood and other tissues. 14 The alternative initiation of COMT translation results in two different variations of the COMT isoform. The MB-COMT is membrane-bound COMT, the longer form of the isoform, while S-COMT or soluble COMT is the shorter version of the isoform (www.uniprot.org). This shorter S-COMT isoform lacks the first 50 amino acids sequence of the longer isoform.
Previous studies in schizophrenia patients have revealed hypomethylation of MB-COMT in the brain, 15 saliva, 16 and peripheral blood. 17 In contrast, the DNA methylation of S-COMT appears to be increased in the peripheral blood as well as in the brain tissues of schizophrenia patients. 18, 19 DNA methylation patterns are suspected to be influenced by environmental factors. 20 The environmental factors that influence DNA methylation are considered as the major confounding factors that contribute to the inconsistency of the psychiatric genetic research. 21 It was found that DNA methylation of several genes had an association with age, gender, smoking, age of onset, and duration of illness. 22, 23 Schizophrenia patients are prone to obesity, and it was found that being overweight is also correlated with DNA methylation. 24 The current study measured the DNA methylation level of COMT in the peripheral blood leukocytes of schizophrenia patients and healthy controls (HC) in order to test its potential use as a peripheral biomarker of schizophrenia. The study focused on the CpG islands at the first 600 bp of the 5 0 upstream, untranslated region of COMT. This promoter region likely initiates the transcription of the MB-COMT isoform. This research also aimed to study the relations of demographic and clinical variables of schizophrenia with COMT DNA methylation.
METHODS

Sample collection
The study was undertaken with approval from the Research and Ethics Committee of the International Islamic University Malaysia (IIUM) and registered under the National Medical Research Registry in Malaysia (NMRR-10-832-6366). We included a total of 138 Malay Malaysian schizophrenia patients who attended the Psychiatry Clinic at Hospital Tengku Ampuan Afzan. DNA samples of 132 Malay Malaysian HC matched for sex and age were randomly selected from archived DNA samples in the Molecular Research Laboratory of the Department of Pathology and Laboratory Medicine at IIUM. The control samples had been collected from a previous study. 25 These healthy subjects were recruited from the Kuantan district in Pahang. A previous report suggested a strong relation between race and epigenetics. 26 Thus, to reduce variability biases, the current study focused on the Malay race.
The patients were diagnosed using the DSM-IV criteria for schizophrenia by two trained psychiatrists. The study excluded patients with neurological disorders and a history of substance abuse. The sociodemographic data and the clinical parameters were retrieved from the participants' medical records. The severity of the clinical symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). All participants provided written informed consent after receiving a detailed description of the study.
DNA isolation and bisulfite conversion
The genomic DNA was derived from peripheral blood leukocyte samples and was isolated using a Gentra Puregene Blood Kit (Qiagen, Germany) following the manufacturer's instructions. The universal methylated human DNA (ZYMO Research, Irvine, CA, USA) was used as the positive control. This enzymatically methylated DNA at all cytosine positions comprising CG dinucleotides was admixed with the universal non-methylated human DNA standard (ZYMO Research) to create samples with different percentages of methylation levels. These DNA mixtures were used to construct a standard curve, which is part of the assessment of the efficiency of the MethyLight Taqman assay.
The absolute DNA quantification of the patient samples and the universal methylated and nonmethylated human DNA were measured using a Qubit 3.0 Fluorometer (Thermo-Fisher Scientific, Waltham, MA, USA). Next, 0.5 μg of the DNA was subjected to bisulfite modification using an EZ DNA Gold methylation kit (ZYMO Research) following the supplier's recommended protocol. The bisulfite modified DNA was eluted and diluted to a final concentration of 10 ng/μL.
MethyLight primer and probe sequences
The COMT (http://www.ensembl.org/; COMT: ENSG00000093010) primer sequence was determined based on the primer design criteria by Wojdacz et al. 27 [15] [16] [17] [18] [19] 29 ). The primer for the reference gene (ALU) was generated based on the published sequence by Olkhov-Mitsel et al. 30 The use of ALU for MethyLight assay has greatly enhanced the detection of DNA as this repetitive element is less sensitive to normalization errors due to aneuploidy and copy number variations. 31 All primers and probes were premixed as PrimeTime qPCR primers (IDTDNA, Coralville, IA, USA). The target region of (A) the current study and previous studies by (B) Abdolmaleky et al., 
MethyLight Taqman assays
The MethyLight Taqman probe protocol was adopted for the quantitation of the methylation level of the COMT gene. The standard curves and the samples consisted of 132 HC; 138 schizophrenia patients were run in single, while the universal methylated human DNA that acted as the positive control was run in duplicate.
The bisulfite-treated universal methylated DNA and non-methylated DNA of 70 ng and 140 ng, respectively, were mixed and diluted into threefold increments from 1:3 (1.67 ng/μL) up to 1:19 683 (0.0003 ng/μL), as described in a previous study by Nabil Fikri et al. 32 The standard curves for the serial dilution of both genes were plotted and are shown in Fig. 2 . The standard curves for the serial percentage of the universal methylated and non-methylated DNA of 0%, 1%, 5%, 10%, 25%, 50%, 75%, and 100% were also generated for the COMT and ALU genes (Fig. 3) . In a PCR of 10 μL, 2 μL of each bisulfite-converted universal control DNA dilution was mixed with 5 μL of 10X SensiFAST Probe NO-ROX (Bioline, London, UK), 2.5 μL of nuclease-free water, and 0.5 μL of the 1X PrimeTime qPCR primer mix. The PCR reactions were performed on a CFX96 real-time PCR (Bio-Rad, Hercules, CA, USA) system with an initial denaturation at 95 C for 10 min, followed by 40 cycles of 95 C for 10 s, and 60 C for 30 s. The CV% of the 15 different assay plates ranged from 1.03-15.99% with a mean of 7%.
A similar PCR reaction protocol was applied to all collected samples and the percentage methylation ratio (PMR) was calculated based on the sample's threshold (Cq) values. The PMR was calculated accordingly to the formula: [(COMT/ALU) mean value sample / (COMT/ALU) mean value universal methylated human DNA] × 100%] as proposed by Olkhov-Mitsel et al. 30 
COMT mRNA gene expression
The highest methylation status and the lowest methylation status were chosen to determine the mRNA gene expression of COMT. The RNA was purified from the blood stored in RNAlater using a Ribopure Blood Kit (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. The RNA concentration was measured using its absorbance at 260/280, and the integrity of the samples was confirmed through denatured gel electrophoresis. iScript cDNA Synthesis (Bio-Rad) was used for the reverse transcription of 75ng RNA following the manufacturer's instructions in a final volume of 20 μL. The primer of the targeted COMT gene 
C to 95 C. The Cq value was used for the relative quantitation of the COMT expression and the mean of the quantification was calculated as ΔΔCt.
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Statistical analysis
Data were analyzed using SPSS 19.0 (SPSS, Chicago, IL, USA). The demographic data were calculated using descriptive statistics. Categorical variables were determined using the χ 2 -test, while parametric variables were compared with an independent samples t-test or analysis of covariance (ANCOVA). Pearson's correlation and regression analysis were also used to compare and predict the COMT DNA methylation with PANSS subdomains. A P-value < 0.05 was considered statistically significant at a 95% confidence interval (CI).
RESULTS
COMT DNA methylation in schizophrenia
To investigate the potential of COMT DNA methylation as a peripheral diagnostic marker of schizophrenia, the study included 138 schizophrenia and 132 HC participants. Samples were matched for sex and sex-specific age. The COMT DNA methylation level (as measured by PMR) was lower in schizophrenia patients than it was in the HC ( 
Subgroup analysis in schizophrenia
An ANCOVA analysis demonstrated a significant difference of COMT DNA methylation between the various groups of body mass index (BMI; F = 5.110, d.f. = 3, P = 0.003) as well as between the types of antipsychotic treatment (F = 5.990, d.f. = 2, P = 0.004; Table 3 ). There were five underweight (BMI < 18. (Table 3) .
The PMR values were inversely correlated with all five subdomains of the PANSS. The Excitement and Depressed subdomains showed a strong inverse correlation (P < 0.001) with the PMR of COMT DNA methylation (Fig. 4) . Subsequently, a linear regression analysis demonstrated that COMT DNA methylation significantly predicted the Excitement and Depressed subdomains of the PANSS (Excitement: b = −11.396, t = −4.760, P < 0.001; Depressed: b = −7.789, t = −3.487, P = 0.001; Table 4 ).
COMT mRNA expression analysis
Five schizophrenia cases each were selected from the highest and the lowest methylation status for the mRNA expression. The PMR values for the highest group (methylated) ranged from 1.53 to 1.70, while the lowest PMR values were 1.17-1.22 (hypomethylated). These findings showed insignificant downregulation of the COMT mRNA expression in the methylated schizophrenia samples as compared to the hypomethylated samples (Fig. 5) .
DISCUSSION COMT DNA methylation in schizophrenia
There are differing opinions regarding the use of peripheral blood leukocytes as surrogate tissue for brain samples in the study of DNA methylation and its role in schizophrenia. However, a number of studies have shown parallel changes of DNA methylation between the brain and peripheral blood leukocytes. [34] [35] [36] [37] [38] In a recent genome-wide DNA methylation analysis, Wockner et al. 34 reported a similarity of the DNA methylation that takes place in the brain and the peripheral blood; both involve more than 90 sites, which may indicate that methylation in the peripheral blood leukocytes can be a promising peripheral diagnostic marker. Previous studies have found hypomethylation of MB-COMT in the brains of schizophrenia and bipolar disorder patients 15 and a similar direction of hypomethylation changes in the saliva of different groups of schizophrenia and bipolar disorder patients. 16 Our current study showed similar hypomethylation in the peripheral blood leukocytes of patients with schizophrenia as compared with the HC. While this observation is preliminary, the findings suggest that the PMR value of MB-COMT DNA methylation in the peripheral blood can be further explored and assessed for its potential use as a diagnostic biomarker of schizophrenia. Since published studies of DNA methylation in schizophrenia patients are still limited, and their findings are conflicting, our study aimed to measure the DNA methylation of COMT using a MethyLight Taqman assay, which is a high throughput assay for the relative quantification of the methylation level using real-time qPCR. In our study, the incidence of COMT DNA methylation in the peripheral blood was lower in schizophrenia patients than in HC for both male and female participants. Despite the fact that we used different methods of DNA methylation, these findings were similar to those of previous studies.
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Subgroup analysis in schizophrenia
The epigenetic differences in COMT DNA methylation measured by PMR values were higher in overweight and obese participants as compared to the normal BMI group. Several theories have attempted to explain the increased weight seen in patients with schizophrenia. 39 The relation of COMT with increased weight gain may be related with its role in regulating dopamine and noradrenaline activities, which contribute to multiple reward-motivated behaviors, such as diet-induced obesity. 40 Because it is a regulator of dopamine metabolism, COMT is indirectly involved in the dopamine hypothesis that has served as the basis of the current antipsychotic treatment protocol in schizophrenia patients. 41 In our study, the incidence of COMT DNA methylation was lower in schizophrenia patients on atypical antipsychotic treatments as compared to those receiving typical antipsychotics and sulpiride. As more than 40% of patients in the atypical groups were on risperidone, further analysis identified similar lower COMT DNA methylation in the risperidone group than in the group prescribed typical antipsychotics. This study was unable to determine the causal role of risperidone in the hypomethylation of COMT. However, because risperidone, an atypical antipsychotic, acts on various types of receptors (either dopaminergic or nondopaminergic neurotransmitters) 42 and the hypomethylation of MB-COMT has been associated with higher MB-COMT gene expression, 15 we postulated that risperidone might affect MB-COMT DNA methylation through a mechanism that has yet to be identified.
The effects of antipsychotics on DNA methylation have been reported in previous studies. Melas et al. 18 discovered that schizophrenia patients treated with haloperidol had a higher degree of global DNA methylation. In contrast, specific hypermethylation of 17 genes involved in dopamine neurotransmission were associated with olanzapine in another study by Melka et al. 43 These findings indicate the significant roles of psychopharmacological treatment in DNA methylation in schizophrenia.
With regards to the relation between COMT DNA methylation and the psycho-pathological symptoms of schizophrenia, the correlation of COMT methylation and PANSS were examined to assess the degree of relation between the two variables. The current study found that the more Excitement and Depressed symptoms, the lower the value of COMT DNA methylation. We carried out a linear regression analysis to assess whether the value of COMT DNA methylation could predict psychopathological symptoms. We found that COMT DNA methylation predicted the Excitement and Depressed symptoms of schizophrenia. COMT-related pathways on the cognitive vulnerability to depression have previously been reviewed, 44 and significant connections of COMT with violent behavior in schizophrenia 45 have been documented in the context of Met158 polymorphism within the gene. Although previous association studies 5, 8 that have linked COMT with schizophrenia symptoms were specific to COMT gene variations, our significant COMT DNA methylation relation with schizophrenia symptoms highly suggested that COMT DNA methylation does contribute to schizophrenia symptoms.
Other correlations of COMT DNA methylation with sex, age, age of disease onset, duration of illness, smoking, and types of schizophrenia were negative.
Our findings of no relation between COMT DNA methylation and sex and age contradicted the general assumption that methylation differs with sex 46 and age. 22 In regards to the age of disease onset, previous evidence has indicated that the global hypomethylation associated with schizophrenia patients presents early in life. 18 However, a genome-wide methylation study covering more than 7000 markers noted a different type of relation between individual markers and their age of presentation as well as the duration of illness. 23 Another important environmental risk factor that contributes to disease development and progression through genetic and epigenetic mechanisms is smoking. 47 Unfortunately, this factor has not been adequately reported in many studies. Based on our findings, there was no relation between the COMT methylation levels and smoking in schizophrenia patients. This may be due to the lack of information obtained from the patients regarding whether or not they were chronic smokers; a previous study showed that long-term, heavy smokers produce epigenetic effects not seen in light smokers. 48 
COMT mRNA expression analysis
Epigenetics play a major role in the regulation of gene expression without changing the DNA sequence. 49 COMT is widely distributed and expressed in the various parts and cell types of the brain and in the peripheral tissues.
14 In contrast to the expectations that MB-COMT would be expressed significantly, 15 our results instead showed that the MB-COMT gene expression had a downregulated trend but was statistically insignificant. Theoretically, the overexpression of MB-COMT should lead to © 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology increased dopamine degradation, which is consistent with the functional evidence that it plays a major role in dopamine neurotransmission and the dopamine hypothesis of schizophrenia. 15 However, another study found that COMT mRNA expression was decreased in first-episode schizophrenia patients; therefore, the downregulation of COMT may be an effect of dopamine hyperfunction that results in negative feedback on the synthesis of catecholamines. 50 This trend implies that the methylation-gene expression is a complex association, and the measurements depend on the methods used, the demographic differences, and the CpG islands studied. 17 The interactions between genotype, DNA methylation, and gene expression in schizophrenia have been documented in previous studies. Some of these studies 15, 51 were related to the COMT gene, while others were not. 52, 53 There were nine documented single nucleotide polymorphisms (SNP) within the 109bp of the CpG island's rich studied region. The minor allele frequency (MAF) of these nine SNP was extremely rare with estimated frequency of <0.1% (Chr22: 19 941 607-19 969 975; www.ensembl.org). Thus, genotyping for these low-prevalence SNP seems unnecessary. Additionally, two important variants within the COMT gene, the A -287 G (rs737865) and Val 158 Met, were not within the scope of the current study.
Limitations
Several limitations of this study should be noted. First, studying samples of schizophrenia patients currently undergoing treatment is not as effective as studying a group of first-episode patients whose genetic effects on clinical symptoms might be better and who have a lesser medication exposure. Second, this cross-sectional method of investigation was not sufficient to stop the antipsychotic treatments based on clinical symptoms and BMI. Furthermore, the dose and duration of use were not accounted for in the statistical analysis due to difficulty in obtaining consistent data. In addition, confounding factors for obesity, such as diet and lifestyle, are difficult to assess and were not investigated in this study. Finally, due to the unavailability of genotype data of the two important variants within the COMT gene, the study was unable to assess the effects of variant genotypes and DNA methylation on gene expression, which might have contributed to the insignificant findings of the gene expression.
Conclusion
In conclusion, we identified a difference in the DNA methylation of COMT in the peripheral blood of patients with schizophrenia as compared to a normal healthy population. Considering the advantage of blood samples in terms of accessibility, the DNA methylation status of the COMT gene could potentially be useful for developing biomarkers for this psychiatric disorder. We also concluded that the methylation changes were influenced by BMI, psychopathological symptoms, and antipsychotic treatments.
